ALPCO Diagnostics
ALPCO Diagnostics is a Salem, NH-based specialty diagnostics company that develops and distributes proprietary automated immunoassay and PCR instrument platforms and 724+ assay kits across gastroenterology, allergy, infectious disease, endocrinology, and immunology for clinical laboratories and life science researchers globally.
- Company typePrivate
- Founded1991
- HeadquartersSalem, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What ALPCO Diagnostics does
ALPCO Diagnostics, legally American Laboratory Products Company, Ltd., is a Salem, New Hampshire-based specialty diagnostics company founded in 1991 and privately held under Ampersand Capital Partners ownership. The company develops and distributes immunodiagnostic and molecular diagnostic products for clinical laboratories and life science researchers, organized around three core instrument platforms: the KleeYa flash chemiluminescence random-access analyzer (processing up to 120 samples per hour with results in 30 minutes), the GeneProof-branded myCROBE sample-to-answer PCR system and croBEE 2.0 nucleic acid extraction platform, and the MADx ALEX2 multiplex allergy testing platform (exclusive North American distribution rights). These platforms support a catalog of 724+ products spanning gastroenterology (calprotectin, pancreatic elastase, lactoferrin, H. pylori), infectious disease (STI PCR panels, HIV, CMV, syphilis), specialty allergy (IgE/IgG testing), immunology, endocrinology (insulin, GLP-1), and therapeutic drug monitoring (adalimumab), with both FDA-cleared clinical diagnostics and Research Use Only products. The 2022 merger with Czech Republic-based GeneProof added real-time PCR capabilities and an extensive European distributor network.
ALPCO's business model is primarily transactional kit and reagent sales with per-unit pricing ranging from ~$454 for standard ELISA kits to over $2,000 for advanced automated assays, supplemented by proprietary instrument placements that drive recurring reagent pull-through. Revenue also flows from a catalog of over 600 life science research kits sold to academic and pharmaceutical researchers. The company reaches customers through a North American direct sales force, an e-commerce storefront at alpco.com, and a global distributor network spanning Europe, Asia-Pacific, Latin America, Middle East, Africa, and Oceania. A 2024 strategic partnership with Revvity's EUROIMMUN extends GeneProof's CE-IVD molecular assay distribution across the European Union.
Quality and regulatory posture is a material part of the operating model: ALPCO holds ISO 13485:2016 certification, FDA establishment registration under 21 CFR 820, and MDSAP certification. Marketing is content-driven (scientific webinars, trade shows at MEDICA, AACC/ADLM, and AAAAI, SEO-optimized content hub, email campaigns). The company is led by CEO Erik Allen with a global management team including six VP-level roles covering business development, product management, sales, quality/regulatory, scientific operations, and finance.
ALPCO Diagnostics firmographics
Firmographics- Name
- ALPCO Diagnostics
- Legal name
- American Laboratory Products Company, Ltd.
- Website
- https://alpco.com
- Company type
- Private
- Founded year
- 1991
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- ALPCO Diagnostics is a Salem, NH-based specialty diagnostics company that develops and distributes proprietary automated immunoassay and PCR instrument platforms and 724+ assay kits across gastroenterology, allergy, infectious disease, endocrinology, and immunology for clinical laboratories and life science researchers globally.
- Ownership category
- akta.pro rank
ALPCO Diagnostics industry classification
Industry- Product category
- In Vitro Diagnostics
- NAICS
- In-Vitro Diagnostic Substance Manufacturing (325413), Analytical Laboratory Instrument Manufacturing (334516)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Surgical & Medical Instruments & Apparatus (3841), Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels) (HLAAALAC)
- akta.pro secondary industries
- Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Autoimmune & Allergy Diagnostics (HLAAALAK)
Keywords
Where ALPCO Diagnostics is headquartered
LocationHeadquarters
- HQ city
- Salem
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
ALPCO Diagnostics business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Diagnostic Instruments: ALPCO sells proprietary automated diagnostic instruments including the KleeYa chemiluminescence platform, myCROBE PCR system, and croBEE nucleic acid extraction system. These instruments enable walk-away sample-to-answer testing for clinical and life science laboratories.
- Assay Kits and Reagents: ALPCO generates revenue from the sale of proprietary assay kits including ELISA, chemiluminescence, and PCR kits across specialties such as gastroenterology, infectious disease, allergy, immunology, endocrinology, and diabetes. Products include Calprotectin, Pancreatic Elastase, Insulin, GLP-1, HIV-1, and STI panels.
- Life Science Research Products: Over 600 kits and reagents for life science research across multiple species and sample types, sold to academic and pharmaceutical researchers. The portfolio covers endocrinology, immunology, gastroenterology, diabetes, and infectious disease research applications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Individual assay kits and reagents with per-unit pricing listed on the website |
Go-to-market motion1 record
Distribution channels3 records
Marketing channels6 records
ALPCO Diagnostics product offering
Product offeringCore offering
ALPCO Diagnostics develops, manufactures, and distributes proprietary immunodiagnostic and molecular diagnostic instruments (KleeYa, myCROBE, croBEE 2.0, ALEX2) together with more than 600 assay kits and reagents for clinical diagnostic laboratories, hospital systems, reference labs, academic researchers, and pharmaceutical/biotech customers. Its specialty focus covers gastroenterology, endocrinology, infectious disease, allergy, immunology, and reproductive health biomarkers, supplied through direct sales in North America and a global distributor footprint of more than 60 countries.
Product overview
ALPCO Diagnostics is a global leader in immunodiagnostics and molecular diagnostics, offering a portfolio of proprietary automated sample-to-answer platforms and diagnostic assays. The core product architecture consists of three main instrument platforms: the KleeYa Flash Chemiluminescence analyzer for automated biomarker testing, the GeneProof molecular diagnostics system (myCROBE sample-to-answer PCR and croBEE nucleic acid extraction), and the MADx ALEX2 multiplex allergy platform for IgE-based testing. These platforms support a comprehensive menu of over 600 diagnostic assays across key specialty areas including gastroenterology (calprotectin, pancreatic elastase, lactoferrin), infectious disease (STI PCR panels, HIV, CMV), allergy (multiplex IgE), immunology (complement system), and endocrinology (insulin, GLP-1). The company also offers plate-based ELISA solutions and the STELLUX chemiluminescence assay product line. Following the 2022 merger with GeneProof, ALPCO expanded from primarily immunoassay-based products to include real-time PCR capabilities, creating an integrated portfolio spanning immunodiagnostics and molecular diagnostics.
Differentiator
Problem solved
Functional benefit
Brands
- KleeYa: Flash Chemiluminescence immunoassay platform for automated biomarker testing
- GeneProof
- MADx
- STELLUX
- ALEX2
Products and services
- KleeYa Automated Flash Chemiluminescence Analyzer Proprietary automated chemiluminescence immunoassay instrument that runs ALPCO's specialty biomarker menu (gastrointestinal, endocrine, allergy, infectious disease, and immunology assays) for clinical and research laboratories.
- myCROBE PCR System Automated PCR amplification system used by molecular diagnostic laboratories to detect infectious disease and genetic targets with ALPCO's PCR reagents and kits.
- croBEE 2.0 Nucleic Acid Extraction System Compact benchtop instrument that automates DNA and RNA extraction to streamline sample preparation ahead of PCR amplification in molecular diagnostic laboratories.
- ALEX2 (MADx) Multiplex Allergy Test Multiplex in vitro allergy diagnostic that simultaneously measures total and specific IgE against a comprehensive panel of allergen extracts and components from a single sample.
- STELLUX Chemiluminescence Assays Specialty chemiluminescence immunoassay reagent kits run on the KleeYa platform for quantitative measurement of gastrointestinal, endocrine, and inflammatory biomarkers.
- Calprotectin Immunoturbidimetric Assay Quantitative fecal calprotectin immunoassay for differentiating inflammatory bowel disease from functional gastrointestinal disorders, used by clinical laboratories on routine chemistry analyzers.
- Plate-based ELISA Kits Comprehensive library of enzyme-linked immunosorbent assay kits covering specialty biomarkers across gastroenterology, endocrinology, infectious disease, allergy, and immunology for research and clinical labs.
- GeneProof PCR Kits Molecular diagnostic PCR kits for infectious disease and genetic testing that laboratories run on the myCROBE system or compatible PCR thermocyclers.
- AutoPlex GI Biomarker Panels Curated multi-analyte gastrointestinal biomarker panels run on ALPCO's automated platforms for specialty gastroenterology testing in clinical and research settings.
Quantifiable outcome
- KleeYa platform processes up to 120 samples per hour with single sample results in 30 minutes
- +2 more outcomes
Companies that use ALPCO Diagnostics
Customer profileSegments3 records
Ideal customer profiles2 records
ALPCO Diagnostics technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
ALPCO Diagnostics partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered major and core.
- Revvity's EUROIMMUNmajorRevvity's EUROIMMUN and ALPCO-GeneProof announced a strategic partnership in April 2024 to expand the availability of GeneProof PCR kits throughout the European Union. The collaboration combines EUROIMMUN's extensive distribution network and support infrastructure with ALPCO-GeneProof's innovative molecular diagnostic technologies. This partnership enhances GeneProof's CE-IVD molecular assay offerings across the EU market.
- GeneProofcoreIn April 2022, ALPCO merged with GeneProof, a molecular diagnostics company based in Brno, Czech Republic, creating a global leader in diagnostic products. The merger expands ALPCO's capabilities in immunoassay testing, real-time PCR testing, and laboratory instrumentation. GeneProof's extensive European distribution network combined with ALPCO's North American presence created significant geographic synergies. GeneProof is now part of the NuvinkaDx portfolio of companies.
- NuvinkaDxcoreNuvinkaDx is the parent company of both ALPCO and GeneProof following the 2022 merger. As of July 2025, NuvinkaDx announced significant product and regulatory milestones for its portfolio companies including ALPCO and GeneProof.
- Macro Array Diagnostics (MADx)majorALPCO is the exclusive North American distributor for Macro Array Diagnostics (MADx), distributing the ALEX2 multiplex allergy testing platform and associated IgE and IgG testing products in North America. The MADx ALEX2 platform enables screening of up to 300 allergens including 117 extracts and 183 molecular allergens. ALPCO actively participates in AAAAI Annual Meetings as the MADx North American distributor.
Scale indicators4 records
Recent moves6 records
Expansion highlights6 records
ALPCO Diagnostics competitors and assessment
Company assessmentDirect peers
- Bio-Rad Laboratories: Bio-Rad is a direct peer in specialty IVD and life science research, offering ELISA kits, immunoassay instruments, molecular diagnostics, and a similarly broad catalog serving clinical and research laboratories globally.
- QIAGEN: QIAGEN is a direct peer in molecular diagnostics sample-to-answer workflows and PCR kits for infectious disease, overlapping GeneProof's PCR menu and instrumentation.
- Tecan: Tecan provides automated immunoassay and sample-preparation platforms used by clinical and research laboratories, overlapping ALPCO's KleeYa and croBEE instrument franchises in laboratory workflow automation.
- DiaSorin: DiaSorin specializes in specialty immunodiagnostics and molecular diagnostics with chemiluminescence platforms (LIAISON) and specialty menus (infectious disease, endocrinology, GI), overlapping ALPCO's KleeYa-based specialty assay portfolio.
- Hologic: Hologic is a direct peer in molecular diagnostics, particularly for STI panels and women's health infectious disease, overlapping GeneProof's CT/NG/MG multiplex PCR kit and broader infectious disease menu.
- DRG International: DRG International is a specialty immunoassay vendor focused on endocrinology and specialty biomarkers, overlapping ALPCO's STELLUX/KleeYa endocrinology and immunology assay menu for clinical and research labs.
- QuidelOrtho: QuidelOrtho competes directly in specialty immunoassays and molecular diagnostics for infectious disease and reproductive health, overlapping ALPCO's STI PCR panels and infectious disease menu.
Broad incumbents
- Merck KGaA / MilliporeSigma: MilliporeSigma serves the same life science research customer base as ALPCO with ELISA kits, antibodies, and laboratory reagents across endocrinology, immunology, and cell biology applications.
- Binding Site (Thermo Fisher Scientific): The Binding Site, part of Thermo Fisher, provides specialty immunodiagnostics (e.g., immune globulin, complement, specialty proteins) that directly compete with ALPCO's immunology and complement assays.
- Revvity (PerkinElmer): Revvity's EUROIMMUN division is both a distribution partner and a broad specialty IVD incumbent with autoimmune, infectious disease and allergy diagnostics menus that compete with several of ALPCO's specialty franchises.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
ALPCO Diagnostics social profiles
Digital presenceALPCO Diagnostics compliance and trust
Trust signalCompliance3 records
ALPCO Diagnostics financial estimates
Financial estimateRevenue estimate
Valuation estimate
ALPCO Diagnostics leadership team
Management profileNumber of profiles
Profiles11 records
ALPCO Diagnostics subsidiaries and ownership
Company hierarchySubsidiaries1 record
ALPCO Diagnostics funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
ALPCO Diagnostics M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about ALPCO Diagnostics
What does ALPCO Diagnostics do?
ALPCO Diagnostics develops, manufactures, and distributes proprietary immunodiagnostic and molecular diagnostic instruments (KleeYa, myCROBE, croBEE 2.0, ALEX2) together with more than 600 assay kits and reagents for clinical diagnostic laboratories, hospital systems, reference labs, academic researchers, and pharmaceutical/biotech customers. Its specialty focus covers gastroenterology, endocrinology, infectious disease, allergy, immunology, and reproductive health biomarkers, supplied through direct sales in North America and a global distributor footprint of more than 60 countries.
Is ALPCO Diagnostics a public or private company?
ALPCO Diagnostics is a private company. It is classified as private equity controlled and is currently operating.
When was ALPCO Diagnostics founded?
ALPCO Diagnostics was founded in 1991. It employs 11 to 50 people.
Where is ALPCO Diagnostics based?
ALPCO Diagnostics is headquartered in Salem, United States, in the North America region.
How does ALPCO Diagnostics make money?
Three revenue lines are on record. Diagnostic Instruments are the primary driver. The others are assay Kits and Reagents and life Science Research Products.
Who are ALPCO Diagnostics's main competitors?
Direct peers on record are Bio-Rad Laboratories, QIAGEN, Tecan, DiaSorin, Hologic, DRG International and QuidelOrtho. Broad incumbents are Merck KGaA / MilliporeSigma, Binding Site (Thermo Fisher Scientific) and Revvity (PerkinElmer).
Does ALPCO Diagnostics have an API?
No public API is recorded for ALPCO Diagnostics.
What industry is ALPCO Diagnostics in?
ALPCO Diagnostics's product category is In Vitro Diagnostics. Its primary akta.pro industry code is HLAAALAC, Microbiology & Infectious Disease Diagnostics (culture, rapid antigen, syndromic panels), with a secondary code of HLAAALAA, Molecular Diagnostics (PCR/qPCR, NGS-based assays). Its NAICS code is 325413 and its SIC code is 2835.